Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant letrozole plus chemotherapy for ER-positive, HER2-negative breast cancer
ACTRN12614000515695Phase 2Completed
- Sponsor
- Breast Cancer Trials
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of letrozole in breast cancer (2 arms), sponsored by Breast Cancer Trials. Primary endpoint: Rate of downstaging to pathologic stage 0 or 1A. Started May 2015; status: completed.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12614000515695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000515695.